中国防痨杂志2025，Vol.47Issue(1)：36-43,8.DOI:10.19982/j.issn.1000-6621.20240317
2018-2023年贵州省利福平敏感MTB/HIV双重感染患者流行特征及治疗转归分析
Characteristics and treatment outcome analysis of MTB/HIV dual infection patients in Guizhou Province from 2018 to 2023
摘要
Abstract
Objective:Analyze characteristics and treatment data of rifampicin sensitive MTB/HIV dual infection patients in Guizhou Province from 2018 to 2023,providing reference basis for optimizing tuberculosis prevention and control measures of Guizhou Province.Methods:The registration information of rifampicin sensitive MTB/HIV dual infection patients in Guizhou Province from 2018 to 2023 was obtained through the"Tuberculosis Information Management System",a subsystem of the"China Disease Prevention and Control Information System",and their characteristics and treatment outcomes were analyzed.Results:From 2018 to 2023,there were a total of 2021 rifampicin sensitive MTB/HIV dual infection cases in Guizhou Province.Age,gender,ethnicity,and occupation were related to MTB/HIV dual infection,with 50.32％(1017/2021)cases aged 40-59,79.76％(1612/2021)being male,69.12％(1397/2021)being Han,and 77.29％(1562/2021)being farmers;1663 cases were successfully treated,with an overall success rate of 82.29％(1663/2021).The successful treatment rates of year 2021 to 2023 showed a downward trend(x2trend=7.232,P=0.007),with the proportion of cured cases increasing from 48.79％(161/330)in 2021 to 53.20％(183/344)in 2023,and the proportion of non-tuberculosis deaths increasing from 10.61％(35/330)in 2021 to 17.44％(60/344)in 2023.The results of multivariable logistic regression analysis showed that compared with new patients,the risk of adverse outcomes was higher for retreatment patients who had experienced a treatment failure previously(OR=5.386,95％CI:1.656-17.516);compared with patients taking 2H-R-Z-E/10H-R-E as primary treatment regime,the risks of adverse outcomes were lower for patients taking 2H-R-Z-E/4H-R(OR=0.433,95％CI:0.309-0.606)and 2H-R-Z-E/7-10H-R-E(OR=0.497,95％CI:0.302-0.818).Conclusion:From 2018 to 2023,the majority of patients with rifampicin sensitive MTB/HIV dual infection in Guizhou Province were male,Han,farmers,and aged 40 to 59.During treatment,attention should be paid to treating opportunistic infections and managing complications,improving treatment compliance and regularity according to the course of treatment,to increase the treatment success rate of patients.关键词
结核,肺/HIV感染/流行病学/治疗结果Key words
Tuberculosis,pulmonary/HIV infections/Epidemiology/Treatment outcome分类
医药卫生引用本文复制引用
李福栋,李进岚,马晓雪,周建,王大福,张玥颖,龚婷婷,饶文,洪峰,李世军..2018-2023年贵州省利福平敏感MTB/HIV双重感染患者流行特征及治疗转归分析[J].中国防痨杂志,2025,47(1):36-43,8.基金项目
贵州省发改委省级基本建设前期工作项目(2020-181-131) Guizhou Provincial Development and Reform Commission Provincial Basic Construction Preliminary Work Project(2020-181-131) （2020-181-131）
